Clinical Trials Browser

Breast Neoplasms

NCT06120283 2026-04-15

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Phase 1 Recruiting

399 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06638307 2026-04-13

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Phase 1 Recruiting

240 enrolled

Breast

Advanced Breast Cancer

NCT05386108 2026-04-06

ELECTRA

Phase 1/2 Recruiting

73 enrolled

BreastCNS

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT04791384 2026-03-31

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Phase 1/2 Terminated

5 enrolled

Breast

Breast Neoplasms

NCT06492616 2026-03-27

ELEGANT

Phase 3 Recruiting

4,220 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT05573126 2026-03-20

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Phase 1/2 Recruiting

95 enrolled

Breast

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

435 enrolled

Breast

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

Phase 3 Completed

478 enrolled 16 charts 2 FDA

Breast

Breast Neoplasms

NCT05618613 2025-05-09

ELONA

Phase 1/2 Terminated

4 enrolled

Breast

Breast Neoplasms

NCT06938711 2025-04-22

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast

Breast Neoplasms

NCT06544577 2024-08-09

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

Recruiting

350 enrolled

Breast

ESR1 Gene Mutation

NCT02338349 2022-08-18

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Phase 1 Completed

57 enrolled

Breast

Advanced ER+, HER2-Negative Breast Cancer

NCT02650817 2022-08-18

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

Phase 1 Completed

16 enrolled

Breast

Breast Neoplasms

Clinical Trials

ELCIN

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

ELECTRA

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

ELEGANT

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

ELEVATE

EMERALD

ELONA

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer